Endari (L-glutamine) is a brand-name oral powder that’s prescribed to reduce complications of sickle cell disease in adults and some children. As with other drugs, Endari can cause side effects, such ...

The Endari (L-glutamine) dose for sickle cell disease is based on body weight and is usually taken twice per day. Your doctor will determine your dosage of this drug. It’s important to take the dosage ...

Sickle cell affects nearly 100,000 people in the United States. Endari has been approved for patients, the first approval for this rare blood disorder in nearly 20 years. Before the FDA's approval, ...

Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a prescription-grade L-glutamine oral powder. The agreement grants NIT ...

Endari (L-glutamine) is a brand-name drug prescribed to help decrease complications of sickle cell disease (SCD) in adults and some children. Endari comes as a powder that’s taken by mouth twice per ...

The U.S. Food and Drug Administration has approved the first drug in nearly 20 years for sickle cell, an inherited disease in which abnormally shaped red blood cells can't properly carry oxygen ...

Endari (L-glutamine; Emmaus Medical) is an amino acid indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients aged 5 years and older. The Food and Drug ...

TORRANCE, Calif., Nov. 3, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today revised prescribing information for Endari® to better ...

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, marketing, and sale of innovative treatments and therapies, including those for rare ...

TORRANCE, Calif., Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today ...

TORRANCE, Calif., Dec. 10, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that it was notified by the Michigan ...